세계의 희귀질환 유전자 검사 시장 : 질환 유형, 제공, 전문 유형, 샘플 유형, 형질 유형, 기술, 연령층, 최종사용자, 국가별 분석과 예측(2023-2033년)

Rare Disease Genetic Testing Market - A Global and Regional Analysis: Focus on Disease Type, Offering, Specialty Type, Sample Type, Trait Type, Technology, Age Group, End User, and Country Analysis - Analysis and Forecast, 2023-2033

US $ 2,750 ￦ 3,837,000

PDF and Excel (1-3 User License)

PDF 및 Excel 보고서를 동일 사업장에서 3명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,250 ￦ 5,930,000

PDF and Excel (Global License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

CAGR

주요 시장 통계
예측 기간	2023-2033년
2023년 평가	46억 3,000만 달러
2033년 예측	166억 9,000만 달러
CAGR :	13.69%

세계의 희귀질환 유전자 검사 시장 규모는 2022년 41억 1,000만 달러에서 예측 기간 중 13.69%의 CAGR로 추이하며, 2033년에는 166억 9,000만 달러 규모로 성장할 것으로 예측됩니다.

세계의 희귀질환 유전자 검사 시장은 희귀질환의 조기 발견에 대한 수요의 증가로 인해 괄목할 만한 성장을 보이고 있습니다. 희귀질환의 유병률 증가가 시장 성장에 중요한 역할을 하고 있습니다. 소아 인구에서 희귀질환의 조기 발견과 예방에 대한 인식이 높아지는 것도 시장 성장에 영향을 미칠 것으로 예상됩니다.

질병 유형별로는 내분비 및 대사성 질환 부문이 2022년 21.88%의 점유율을 보이며 시장을 주도하고 있습니다. 내분비 및 대사성 질환은 일반 인구에서 높은 유병률을 보이는 경우가 많아 진단과 관리가 특히 어렵습니다. 진단에는 NGS와 같은 유전자 검사가 사용됩니다. 또한 바이오마커 분석, 신생아 선별검사, 분자진단 기술도 포함됩니다.

전문 분야별로 보면 분자 유전학 검사 부문이 2022년 58.89%의 점유율로 시장을 주도할 것으로 예상됩니다. 분자 유전학 검사의 인기가 높아지는 주요 이유는 희귀질환을 앓고 있는 개인과 가족의 유전 상담 및 가족 계획에 중요한 정보를 제공하기 때문입니다. 특정 유전자 변이를 확인함으로써 가족은 질병의 유전 가능성에 대한 인사이트을 얻을 수 있고, 미래 세대에 질병을 물려줄 위험을 평가할 수 있습니다.

지역별로 보면 북미와 유럽은 기술적으로 진보된 산업을 보유하고 있으며, R&D에 상당한 예산을 배정하고 있습니다. 희귀질환 검사도 가장 많이 이루어지고 있으며, 이들 지역이 세계 희귀질환 유전자 검사 시장에서 가장 큰 점유율을 차지하고 있습니다.

주요 기업 개요

세계의 희귀질환 유전자 검사 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 규제 환경, 시장 규모 추이 및 예측, 각종 부문별·지역별 상세 분석, 특허 동향, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 시장

• 세계 시장의 전망
• 산업 분석
  • 규제 프레임워크
  • 특허 분석
  • 자금조달 시나리오
• 시장 역학
  • 개요
  • 시장 촉진요인
  • 시장이 해결해야 할 과제
  • 시장 기회

제2장 경쟁 인사이트

• 경쟁 벤치마킹
  • 주요 전략과 도입
  • 시장 점유율 분석
  • 성장 점유율 분석

제3장 세계의 희귀질환 유전자 검사 시장 : 질환 유형별

• 개요
• 소화기 질환
• 내분비 대사질환
• 순환기 질환
• 신경질환
• 혈액 종양학 질환
• 피부과 질환
• 기타

제4장 세계의 희귀질환 유전자 검사 시장 : 제공별

• 개요
• 제품
• 서비스

제5장 세계의 희귀질환 유전자 검사 시장 : 전문 분야별

• 개요
• 분자유전학적 검사
• 염색체 유전자 검사
• 생화학적 유전자 검사

제6장 세계의 희귀질환 유전자 검사 시장 : 샘플 유형별

• 개요
• DNA 샘플
• 구강 스왑 샘플
• 혈액 샘플
• 타액 샘플
• 기타

제7장 세계의 희귀질환 유전자 검사 시장 : 형질 유형별

• 개요
• 유전 형질
• 후천적 형질

제8장 세계의 희귀질환 유전자 검사 시장 : 기술별

• 개요
• 중합효소 연쇄 반응(PCR)
• 차세대 시퀀스(NGS)
  • 전게놈 시퀀싱
  • 전엑솜 시퀀싱
• 마이크로어레이
• 생어 시퀀싱
• 기타

제9장 세계의 희귀질환 유전자 검사 시장 : 연령층별

• 개요
• 출생전
• 신생아·유아
• 소아·사춘기
• 성인

제10장 세계의 희귀질환 유전자 검사 시장 : 최종사용자별

• 개요
• 병원
• 진단 랩
• 기타

제11장 세계의 희귀질환 유전자 검사 시장 : 지역별

• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 기타 지역

제12장 기업 개요

KSA

영문 목차

영문목차

“Global Rare Disease Genetic Testing Market to Reach $16.69 Billion by 2033.”

Introduction of Rare Disease Genetic Testing

The global rare disease genetic testing market was valued at $4.11 billion in 2022 and is anticipated to reach $16.69 billion by 2033, witnessing a CAGR of 13.69% during the forecast period 2023-2033. Cutting-edge technologies, such as whole-genome sequencing (WGS) and whole-exome sequencing (WES), involve the analysis of an individual's complete genetic code (genome) or specific protein-coding regions (exome), respectively. These methods help identify genetic variations, mutations, or abnormalities responsible for rare diseases.

KEY MARKET STATISTICS
Forecast Period	2023 - 2033
2023 Evaluation	$4.63 Billion
2033 Forecast	$16.69 Billion
CAGR	13.69%

Market Introduction

Before the advent of NGS (which includes WGS and WES), physicians relied on the Sanger sequencing-based tests, which could detect rare diseases but were extremely time-consuming. Additionally, till all the tests were completed, physicians had to rely on a general diagnostic odyssey or general diagnosis until definitive results were available. This delayed the treatment process. As per BIS Research, the global rare disease genetic testing market includes panels and tests that can be used for more rare disease genetic testing. These are predominantly polymerase chain reaction (PCR) and next-generation sequencing (NGS) based tests, panels, and assays. The most common rare disease genetic testing panels include gastroenterology, endocrine and metabolism, and neurology disease, among others.

Industrial Impact

The global rare disease genetic testing market has witnessed significant growth, attributed to the increasing demand for early detection of rare diseases. The increasing prevalence of rare diseases has played a critical role in market growth. Furthermore, growing recognition and emphasis on early detection and prevention of rare diseases in pediatric populations around the world are also expected to influence market growth.

Rare disease genetic testing has immense potential to deliver next-level healthcare solutions. For instance, in January 2023, BGI Genomics, in collaboration with the National Centre for Cardiovascular Diseases, Fuwai Hospital, and the State Key Laboratory of Cardiovascular Diseases, developed the "CardioGen automated interpretation system," which serves as the genotype and phenotype database of monogenic cardiovascular disease. Other factors also impact the market growth, including increased patient demand and low turnaround time of these tests.

Market Segmentation:

Segmentation 1: by Disease Type

• Gastroenterology Disease
• Endocrine and Metabolism Disease
• Cardiovascular Disease
• Neurology Disease
• Hematology and Oncology Disease
• Dermatology Disease
• Other Diseases

Endocrine and Metabolism Disease Segment to Dominate the Global Rare Disease Genetic Testing Market (by Disease Type)

Based on disease type, the rare disease genetic testing market is led by endocrine and metabolism, which held a 21.88% share in 2022. The burden of endocrine and metabolism diseases often has a high prevalence in the general population, making their diagnosis and management particularly challenging. Their diagnosis addresses genetic testing such as NGS. Further, it also includes biomarker analysis, newborn screening, and molecular diagnostic techniques.

Segmentation 2: Offering

• Products
• Services

Services Segment to Dominate the Global Rare Disease Genetic Testing Market (by Offering)

Based on offerings, the rare disease genetic testing market is led by services, which held an 81.58% share in 2022. Services are specifically tailored to meet the distinct requirements of individuals affected by rare diseases, healthcare professionals, and researchers engaged in this field. The availability of these services complements the use of diagnostic products and facilitates comprehensive and personalized rare disease genetic testing.

Segmentation 3: by Specialty Type

• Molecular Genetic Tests
• Chromosomal Genetic Tests
• Biochemical Genetic Tests

Molecular Genetic Tests Occupying the Largest Share in the Market (by Specialty Type)

Based on specialty type, the rare disease genetic testing market is led by molecular genetic tests, which held a 58.89% share in 2022. The key reason for the increasing popularity of molecular genetic testing is that it provides crucial information for genetic counseling and family planning for individuals and families affected by rare diseases. By identifying specific genetic mutations, families can gain insights into the likelihood of disease inheritance and assess the risk of passing on the condition to future generations. This type of testing is utilized to identify genetic disorders in newborns, allowing for prompt intervention and treatment initiation.

Segmentation 4: by Sample Type

• DNA Sample
• Buccal Swab Sample
• Blood Sample
• Saliva Sample
• Others

Blood Sample to Witness the Highest Growth Between 2023 and 2033

Based on sample type, the rare disease genetic testing market is led by blood samples, and it held a 33.99% share in 2022. Blood samples undergo processing to isolate different components, including white blood cells, serum, or plasma. These isolated components are then subjected to further analysis to detect genetic abnormalities, identify biochemical markers, or explore other diagnostic indicators. Genetic testing methods such as PCR, DNA sequencing, and microarrays can be employed on blood samples to identify specific genetic mutations that are associated with rare diseases.

Segmentation 5: by Trait Type

• Inherited Trait
• Acquired Trait

Inherited Trait to Witness the Highest Growth between 2023 and 2033

Based on trait type, the rare disease genetic testing market is led by inherited traits, which held an 82.59% share in 2022. Inherited traits are characteristics or conditions that are passed down from parents to their offspring through genetic material, i.e., DNA. These traits result from variations or mutations in the genes and can increase the risk of developing certain rare diseases.

Segmentation 6: by Technology

• Sanger Sequencing
• PCR
• NGS
• Microarrays
• Others (Targeted Cytogenetics, Karyotyping, and FISH)

NGS to Dominate the Global Rare Disease Genetic Testing Market (by Technology)

Based on technology, the rare disease genetic testing market is led by next-generation sequencing (NGS), and it held a 43.80% share in 2022. NGS technology provides higher sensitivity and specificity in detecting genetic variants, including single-nucleotide variants (SNVs), insertions, deletions, and structural rearrangements. This technology also extends its applications to non-invasive prenatal testing, including the detection of fetal chromosomal abnormalities associated with certain rare genetic conditions.

Segmentation 7: by Age Group

• Prenatal
• Neonate and Infant
• Children and Adolescent
• Adult

Prenatal to Witness the Highest Growth between 2023 and 2033

Based on age group, the rare disease genetic testing market is led by the prenatal age group, which held a 39.68% share in 2022. Prenatal testing and diagnostics play a crucial role in identifying potential rare diseases and congenital abnormalities in the fetus. Prenatal testing methods such as chorionic villus sampling (CVS) and amniocentesis are employed to detect genetic disorders or developmental issues.

Segmentation 8: by End User

• Hospital
• Diagnostics Laboratories
• Other End Users

Hospitals to Dominate the Global Rare Disease Genetic Testing Market (by End User)

Based on end users, the rare disease genetic testing market is led by hospitals, which recorded a 53.12% share in 2022. Hospitals are at the forefront of adopting syndromic testing panels into routine healthcare procedures. Hospitals, particularly in leading regions such as North America and Europe, and also to a certain extent in Asia-Pacific, have incorporated syndromic testing panels and assays to provide superior care to patients.

Segmentation 9: by Region

• North America - U.S., Canada

• Europe - Germany, U.K., France, Italy, Russia, Spain, and Rest-of-Europe

• Asia-Pacific - Japan, India, China, South Korea, Australia, Singapore, and Rest-of-Asia-Pacific

• Latin America - Brazil, Mexico, and Rest-of-Latin America

• Rest-of-the-World

Regions such as North America and Europe have technologically advanced industries and allocate considerable budgets to research and development (R&D) activities. Moreover, a maximum number of rare disease testing is done there, due to which these regions hold the maximum share in the global rare disease genetic testing market.

Recent Developments in the Rare Disease Genetic Testing Market

• In April 2023, Agilent Technologies, Inc. and Theragen Bio collaborated in South Korea to advance bioinformatic solutions for cancer genomic profiling.

• In April 2023, 3 billion receives accreditation from the California Department of Public Health (CDPH) as a clinical laboratory. With the CDPH accreditation, hospitals throughout California will now be able to utilize 3 billion's genetic tests for diagnostic purposes and can claim insurance for the tests.

• In February 2023, Akili Labs and BGI Genomics established the first commercial clinical sequencing facility in Africa.

• In January 2023, Premier Research and CENTOGENE formed a strategic partnership to hasten and reduce the risk of clinical development for rare diseases.

• In February 2023, Illumina delivers the first NovaSeq X Plus sequencer and workflow insights on Illumina Complete Long Reads unveiled at Advances in Genome Biology and Technology (AGBT).

• In March 2023, Invitae Announces Partnership with Epic to Streamline Genetic Testing. Through Aura, Epic's specialty diagnostics suite, Invitae will streamline interactions with provider organizations in the Epic community, making test result information available in providers' usual workflows so that it's easier to use genetic insights to inform treatment decisions.

Demand - Drivers, Challenges, and Opportunities

Market Demand Drivers:

• Rapid Technological Advancements in Rare Disease Diagnosis: Technological advancements, such as next-generation sequencing (NGS), targeted gene panels, and artificial intelligence (AI)-based algorithms, have significantly improved diagnostic accuracy for rare diseases. NGS enables comprehensive genomic analysis, allowing for the identification of disease-causing genetic mutations with higher precision. By identifying the underlying genetic mechanisms and individualizing treatment plans, technological advancements are improving patient outcomes, patient satisfaction, and overall market growth. These advancements have also led to the emergence of new areas of rare disease genetic testing, which have opened up new avenues for research and drug discovery.

• Rising Prevalence of Genetic Disorders and Congenital Disorders: The rising prevalence of genetic disorders and congenital disorders has a significant impact on the growth of the global rare disease genetic testing market. Increased demand for diagnostic services, expansion of screening programs, focus on personalized medicine, research and development initiatives, supportive regulatory environment, and patient advocacy all contribute to the expanding market. Furthermore, the rising prevalence led to an expansion of screening programs. Governments and healthcare organizations are implementing newborn screening programs and prenatal genetic testing initiatives to identify these disorders early.

• Growing Recognition and Emphasis on Early Detection and Prevention of Rare Diseases in Paediatric Populations: Increased consumer demand for early detection and prevention, coupled with a focus on personalized medicine and precision healthcare, is expected to fuel the growth of the global rare disease market. Awareness and education, patient empowerment, expanded screening programs, preventive healthcare strategies, supportive policies, and insurance coverage are all contributing to the expansion of diagnostic services and driving market demand for rare disease genetic testing.

Market Challenges:

• Lack of Consolidation of Information Leading to Difficulty in Diagnosis: The lack of consolidation of information and the resulting difficulty in diagnosis poses significant challenges for the global rare disease genetic testing market. Rare diseases often have limited available information, fragmented research findings, and scattered expertise. The vast number of rare diseases, each with its unique set of symptoms and genetic variations, makes it challenging to consolidate comprehensive knowledge and expertise in a centralized manner.

• Significant Capital Requirement for Research and Development Hindering Global Expansion Efforts: The significant capital requirement for research and development (R&D) poses a notable challenge for the global rare disease genetic testing market. Research and development in the field of rare diseases often involve extensive genetic studies, clinical trials, and the development of innovative diagnostic tools and therapies. These activities require substantial financial investment, as they involve specialized expertise, laboratory infrastructure, regulatory compliance, and patient recruitment. The high costs associated with R&D act as a barrier, particularly for smaller companies and research institutions with limited resources, hindering their ability to undertake comprehensive research and development efforts. Rare diseases, by definition, affect a small patient population. Hence, the limited commercial market potential for treatments and diagnostics creates challenges in attracting sufficient private investment.

Market Opportunities:

• Whole-Genome Sequencing Putting an End to the Rare Disease Diagnostic Odysseys: Whole-genome sequencing (WGS) has the potential to put an end to rare disease genetic testing odysseys and presents significant opportunities for the global rare disease genetic testing market. This technology enables a comprehensive analysis of an individual's entire genome, providing a comprehensive view of the genetic variations and mutations. This approach allows for the detection of both common and rare genetic variants, including those associated with rare diseases.

• AI-Based Diagnostic Tools Diagnosing Rare Diseases by Identifying Potential Diagnoses: AI-based diagnostic tools that utilize machine learning and artificial intelligence algorithms present significant opportunities for the global rare disease market by improving the diagnosis of rare diseases. Artificial intelligence (AI) and machine learning algorithms are revolutionizing rare disease genetic testing by analyzing large datasets, identifying patterns, and making accurate predictions. For instance, in July 2021, Sema4, the parent organization of GeneDx, successfully concluded a transaction with CM Life Sciences, marking its debut as a publicly traded company. The company now operates as an AI-driven genomics and clinical data platform company.

• Transitioning toward Increased Genetics Coverage in Reimbursement Policies: Transitioning toward increased genetics coverage in reimbursement policies presents a valuable opportunity for the global rare disease genetic testing market. It improves access to genetic testing, encourages early diagnosis and intervention, supports research and development efforts, stimulates innovation, reduces financial burdens for patients, and aligns with the principles of personalized medicine. These factors collectively contribute to improved diagnostic rates and advancements in rare disease management.

How Can This Report Add Value to an Organization?

• Product/Innovation Strategy: The global rare disease genetic testing market has been extensively segmented on the basis of various categories, such as disease type, specialty type, sample type, end-user, and region. This can help readers understand which segments account for the largest share and which are well-positioned to grow in the coming years.

• Growth/Marketing Strategy: Partnerships, collaborations, product launches, and upgrades accounted for the maximum number of key developments, i.e., nearly 86.2% of the total developments in the global rare disease genetic testing market were between January 2021 and June 2023.

• Competitive Strategy: The global rare disease genetic testing market has numerous established players paving their way into providing tests, panels, and assays in the market. Key players in the global rare disease genetic testing market analyzed and profiled in the study involve established players offering various disease-specific panels and multiplex instruments.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Key Companies Profiled:

Table of Contents

1 Market

• 1.1 Global Market Outlook
  • 1.1.1 Product Definition
  • 1.1.2 Inclusion and Exclusion Criteria
    • 1.1.2.1 Inclusion Criteria
    • 1.1.2.2 Exclusion Criteria
  • 1.1.3 Market Overview
    • 1.1.3.1 Market Footprint
    • 1.1.3.2 Market Size and Future Growth Potential
  • 1.1.4 COVID-19 Impact on the Market
    • 1.1.4.1 Impact on Research and Clinical Operations
    • 1.1.4.2 COVID-19 Impact: Current Scenario of the Market
• 1.2 Industry Analysis
  • 1.2.1 Regulatory Framework
    • 1.2.1.1 Legal Requirements and Framework in the U.S.
    • 1.2.1.2 Legal Requirements and Framework in Europe
      • 1.2.1.2.1 U.K.
      • 1.2.1.2.2 Spain
    • 1.2.1.3 Legal Requirements and Framework in Asia-Pacific
      • 1.2.1.3.1 Japan
      • 1.2.1.3.2 China
      • 1.2.1.3.3 India
      • 1.2.1.3.4 Taiwan
  • 1.2.2 Patent Analysis
    • 1.2.2.1 Patent Filing Trend (by Country)
    • 1.2.2.2 Patent Filing Trend (by Year)
  • 1.2.3 Funding Scenario
• 1.3 Market Dynamics
  • 1.3.1 Overview
  • 1.3.2 Market Drivers
    • 1.3.2.1 Rapid Technological Advancements in Rare Disease Diagnosis
    • 1.3.2.2 Rising Prevalence of Genetic Disorders and Congenital Disorders
    • 1.3.2.3 Growing Recognition and Emphasis on Early Detection and Prevention of Rare Diseases in Pediatric Populations
  • 1.3.3 Market Challenges
    • 1.3.3.1 Lack of Consolidation of Information Leading to Difficulty in Diagnosis
    • 1.3.3.2 Significant Capital Requirement for Research and Development Hindering Global Expansion Efforts
  • 1.3.4 Market Opportunities
    • 1.3.4.1 Whole Genome Sequencing Putting an End to the Rare Disease Genetic Testing Odysseys
    • 1.3.4.2 AI-Based Diagnostic Tools Diagnosing Rare Diseases by Identifying Potential Diagnoses
    • 1.3.4.3 Transitioning toward Increased Genetics Coverage in Reimbursement Policies

2 Competitive Insights

• 2.1 Competitive Benchmarking
  • 2.1.1 Key Strategies and Developments
    • 2.1.1.1 Funding Activities
    • 2.1.1.2 New Offerings, Product Upgradation, and Approvals
    • 2.1.1.3 Mergers and Acquisitions
    • 2.1.1.4 Partnerships, Collaborations, And Business Expansion
  • 2.1.2 Market Share Analysis
    • 2.1.2.1 Rare Disease Genetic Testing Market, Market Share Analysis of Companies Offering Products
    • 2.1.2.2 Rare Disease Genetic Testing Market, Market Share Analysis of Companies Offering Services.
  • 2.1.3 Growth-Share Analysis
    • 2.1.3.1 By Disease Type
    • 2.1.3.2 By Technology Type

3 Global Rare Disease Genetic Testing Market (by disease type), 2022-2033

• 3.1 Overview
• 3.2 Gastroenterology Disease
• 3.3 Endocrine and Metabolism Disease
• 3.4 Cardiovascular Disease
• 3.5 Neurology Disease
• 3.6 Hematology and Oncology Disease
• 3.7 Dermatology Disease
• 3.8 Other Diseases

4 Global Rare Disease Genetic Testing Market (by Offering), 2022-2033

• 4.1 Overview
• 4.2 Products
• 4.3 Services

5 Global Rare Disease Genetic Testing Market (by Specialty Type), 2022-2033

• 5.1 Overview
• 5.2 Molecular Genetic Tests
• 5.3 Chromosomal Genetic Tests
• 5.4 Biochemical Genetic Tests

6 Global Rare Disease Genetic Testing Market (by Sample Type), 2022-2033

• 6.1 Overview
• 6.2 DNA Sample
• 6.3 Buccal Swab Sample
• 6.4 Blood Sample
• 6.5 Saliva Sample
• 6.6 Others

7 Global Rare Disease Genetic Testing Market (by Trait Type), 2022-2033

• 7.1 Overview
• 7.2 Inherited Trait
• 7.3 Acquired Trait

8 Global Rare Disease Genetic Testing Market (by Technology), 2022-2033

• 8.1 Overview
• 8.2 Polymerase Chain Reaction (PCR)
• 8.3 Next-Generation Sequencing (NGS)
  • 8.3.1 Whole Genome Sequencing
  • 8.3.2 Whole Exome Sequencing
• 8.4 Microarrays
• 8.5 Sanger Sequencing
• 8.6 Other Technologies

9 Global Rare Disease Genetic Testing Market (by Age Group), 2022-2033

• 9.1 Overview
• 9.2 Prenatal
• 9.3 Neonate and Infant
• 9.4 Children and Adolescent
• 9.5 Adult

10 Global Rare Disease Genetic Testing Market (by End User), 2022-2033

• 10.1 Overview
• 10.2 Hospitals
• 10.3 Diagnostic Laboratories
• 10.4 Other End User

11 Global Rare Disease Genetic Testing Market (by Region)

• 11.1 North America Rare Disease Genetic Testing Market
  • 11.1.1 Market Dynamics
    • 11.1.1.1 Impact Analysis
  • 11.1.2 Market Sizing and Forecast
    • 11.1.2.1 North America Rare Disease Genetic Testing Market (by Disease Type)
    • 11.1.2.2 North America Rare Disease Genetic Testing Market (by Technology)
    • 11.1.2.3 North America Rare Disease Genetic Testing Market (by Country)
      • 11.1.2.3.1 U.S.
        • 11.1.2.3.1.1 Market Dynamics
        • 11.1.2.3.1.2 Market Size and Forecast
        • 11.1.2.3.1.2.1 U.S. Rare Disease Genetic Testing Market (by Disease Type)
        • 11.1.2.3.1.2.2 U.S. Rare Disease Genetic Testing Market (by Technology)
      • 11.1.2.3.2 Canada
        • 11.1.2.3.2.1 Market Dynamics
        • 11.1.2.3.2.2 Market Size and Forecast
        • 11.1.2.3.2.2.1 Canada Rare Disease Genetic Testing Market (by Disease Type)
        • 11.1.2.3.2.2.2 Canada Rare Disease Genetic Testing Market (by Technology)
• 11.2 Europe Rare Disease Genetic Testing Market
  • 11.2.1 Market Dynamics
    • 11.2.1.1 Impact Analysis
  • 11.2.2 Market Sizing and Forecast
    • 11.2.2.1 Europe Rare Disease Genetic Testing Market (by Disease Type)
    • 11.2.2.2 Europe Rare Disease Genetic Testing Market (by Technology)
    • 11.2.2.3 Europe Rare Disease Genetic Testing Market (by Country)
      • 11.2.2.3.1 Germany
        • 11.2.2.3.1.1 Market Dynamics
        • 11.2.2.3.1.2 Market Size and Forecast
        • 11.2.2.3.1.2.1 Germany Rare Disease Genetic Testing Market (by Disease Type)
        • 11.2.2.3.1.2.2 Germany Rare Disease Genetic Testing Market (by Technology)
      • 11.2.2.3.2 U.K.
        • 11.2.2.3.2.1 Market Dynamics
        • 11.2.2.3.2.2 Market Size and Forecast
        • 11.2.2.3.2.2.1 U.K Rare Disease Genetic Testing Market (by Disease Type)
        • 11.2.2.3.2.2.2 U.K. Rare Disease Genetic Testing Market (by Technology)
      • 11.2.2.3.3 France
        • 11.2.2.3.3.1 Market Dynamics
        • 11.2.2.3.3.2 Market Size and Forecast
        • 11.2.2.3.3.2.1 France Rare Disease Genetic Testing Market (by Disease Type)
        • 11.2.2.3.3.2.2 France Rare Disease Genetic Testing Market (by Technology)
      • 11.2.2.3.4 Italy
        • 11.2.2.3.4.1 Market Dynamics
        • 11.2.2.3.4.2 Market Size and Forecast
        • 11.2.2.3.4.2.1 Italy Rare Disease Genetic Testing Market (by Disease Type)
        • 11.2.2.3.4.2.2 Italy Rare Disease Genetic Testing Market (by Technology)
      • 11.2.2.3.5 Spain
        • 11.2.2.3.5.1 Market Dynamics
        • 11.2.2.3.5.2 Market Size and Forecast
        • 11.2.2.3.5.2.1 Spain Rare Disease Genetic Testing Market (by Disease Type)
        • 11.2.2.3.5.2.2 Spain Rare Disease Genetic Testing Market (by Technology)
      • 11.2.2.3.6 Russia
        • 11.2.2.3.6.1 Market Dynamics
        • 11.2.2.3.6.2 Market Size and Forecast
        • 11.2.2.3.6.2.1 Russia Rare Disease Genetic Testing Market (by Disease Type)
        • 11.2.2.3.6.2.2 Russia Rare Disease Genetic Testing Market (by Technology)
      • 11.2.2.3.7 Rest-of-Europe
        • 11.2.2.3.7.1 Market Dynamics
        • 11.2.2.3.7.2 Market Size and Forecast
        • 11.2.2.3.7.2.1 Rest-of-Europe Rare Disease Genetic Testing Market (by Disease Type)
        • 11.2.2.3.7.2.2 Rest-of-Europe Rare Disease Genetic Testing Market (by Technology)
• 11.3 Asia-Pacific Rare Disease Genetic Testing Market
  • 11.3.1 Market Dynamics
    • 11.3.1.1 Impact Analysis
  • 11.3.2 Market Size and Forecast
    • 11.3.2.1 Asia-Pacific Rare Disease Genetic Testing Market (by Disease Type)
    • 11.3.2.2 Asia-Pacific Rare Disease Genetic Testing Market (by Technology)
    • 11.3.2.3 Asia-Pacific Rare Disease Genetic Testing Market (by Country)
      • 11.3.2.3.1 Japan
        • 11.3.2.3.1.1 Market Dynamics
        • 11.3.2.3.1.2 Market Size and Forecast
        • 11.3.2.3.1.2.1 Japan Rare Disease Genetic Testing Market (by Disease Type)
        • 11.3.2.3.1.2.2 Japan Rare Disease Genetic Testing Market (by Technology)
      • 11.3.2.3.2 China
        • 11.3.2.3.2.1 Market Dynamics
        • 11.3.2.3.2.2 Market Size and Forecast
        • 11.3.2.3.2.2.1 China Rare Disease Genetic Testing Market (by Disease Type)
        • 11.3.2.3.2.2.2 China Rare Disease Genetic Testing Market (by Technology)
      • 11.3.2.3.3 Australia
        • 11.3.2.3.3.1 Market Dynamics
        • 11.3.2.3.3.2 Market Size and Forecast
        • 11.3.2.3.3.2.1 Australia Rare Disease Genetic Testing Market (by Disease Type)
        • 11.3.2.3.3.2.2 Australia Rare Disease Genetic Testing Market (by Technology)
      • 11.3.2.3.4 South Korea
        • 11.3.2.3.4.1 Market Dynamics
        • 11.3.2.3.4.2 Market Size and Forecast
        • 11.3.2.3.4.2.1 South Korea Rare Disease Genetic Testing Market (by Disease Type)
        • 11.3.2.3.4.2.2 South Korea Rare Disease Genetic Testing Market (by Technology)
      • 11.3.2.3.5 India
        • 11.3.2.3.5.1 Market Dynamics
        • 11.3.2.3.5.2 Market Size and Forecast
        • 11.3.2.3.5.2.1 India Rare Disease Genetic Testing Market (by Disease Type)
        • 11.3.2.3.5.2.2 India Rare Disease Genetic Testing Market (by Technology)
      • 11.3.2.3.6 Singapore
        • 11.3.2.3.6.1 Market Dynamics
        • 11.3.2.3.6.2 Market Size and Forecast
        • 11.3.2.3.6.2.1 Singapore Rare Disease Genetic Testing Market (by Disease Type)
        • 11.3.2.3.6.2.2 Singapore Rare Disease Genetic Testing Market (by Technology)
      • 11.3.2.3.7 Rest-of-Asia-Pacific
        • 11.3.2.3.7.1 Market Dynamics
        • 11.3.2.3.7.2 Market Size and Forecast
        • 11.3.2.3.7.2.1 Rest-of-Asia-Pacific Rare Disease Genetic Testing Market (by Disease Type)
        • 11.3.2.3.7.2.2 Rest-of-Asia-Pacific Rare Disease Genetic Testing Market (by Technology)
• 11.4 Latin America Rare Disease Genetic Testing Market
  • 11.4.1 Market Dynamics
    • 11.4.1.1 Impact Analysis
  • 11.4.2 Market Size and Forecast
    • 11.4.2.1 Latin America Rare Disease Genetic Testing Market (by Disease Type)
    • 11.4.2.2 Latin America Rare Disease Genetic Testing Market (by Technology)
    • 11.4.2.3 Latin America Rare Disease Genetic Testing Market (by Country)
      • 11.4.2.3.1 Brazil
        • 11.4.2.3.1.1 Market Dynamics
        • 11.4.2.3.1.2 Market Size and Forecast
        • 11.4.2.3.1.2.1 Brazil Rare Disease Genetic Testing Market (by Disease Type)
        • 11.4.2.3.1.2.2 Brazil Rare Disease Genetic Testing Market (by Technology)
      • 11.4.2.3.2 Mexico
        • 11.4.2.3.2.1 Market Dynamics
        • 11.4.2.3.2.2 Market Size and Forecast
        • 11.4.2.3.2.2.1 Mexico Rare Disease Genetic Testing Market (by Disease Type)
        • 11.4.2.3.2.2.2 Mexico Rare Disease Genetic Testing Market (by Technology)
      • 11.4.2.3.3 Rest-of-Latin America
        • 11.4.2.3.3.1 Market Dynamics
        • 11.4.2.3.3.2 Market Size and Forecast
        • 11.4.2.3.3.2.1 Rest-of-Latin America Rare Disease Genetic Testing Market (by Disease Type)
        • 11.4.2.3.3.2.2 Rest-of-Latin America Rare Disease Genetic Testing Market (by Technology)
• 11.5 Rest-of-the-World Rare Disease Genetic Testing Market
  • 11.5.1 Market Dynamics
    • 11.5.1.1 Impact Analysis
  • 11.5.2 Market Size and Forecast
    • 11.5.2.1 Rest-of-the-World Rare Disease Genetic Testing Market (by Disease Type)
    • 11.5.2.2 Rest-of-the-World Rare Disease Genetic Testing Market (by Technology)

12 Company Profiles

• 12.1 Overview
  • 12.1.1 23andMe Holding Co.
    • 12.1.1.1 Company Overview
    • 12.1.1.2 Role of 23andMe Holding Co. in the Global Rare Disease Genetic Testing Market
    • 12.1.1.3 Financials
    • 12.1.1.4 Recent Developments
    • 12.1.1.5 Analyst Perspective
  • 12.1.2 3billion, Inc.
    • 12.1.2.1 Company Overview
    • 12.1.2.2 Role of 3billion, Inc. in the Global Rare Disease Genetic Testing Market
    • 12.1.2.3 Recent Developments
    • 12.1.2.4 Analyst Perspective
  • 12.1.3 Agilent Technologies, Inc.
    • 12.1.3.1 Company Overview
    • 12.1.3.2 Role of Agilent Technologies, Inc. in the Global Rare Disease Genetic Testing Market
    • 12.1.3.3 Financials
    • 12.1.3.4 Recent Developments
    • 12.1.3.5 Analyst Perspective
  • 12.1.4 Konica Minolta (Ambry Genetics, Inc.)
    • 12.1.4.1 Company Overview
    • 12.1.4.2 Role of Konica Minolta (Ambry Genetics, Inc.) in the Global Rare Disease Genetic Testing Market
    • 12.1.4.3 Financials
    • 12.1.4.4 Recent Developments
    • 12.1.4.5 Analyst Perspective
  • 12.1.5 BGI Group
    • 12.1.5.1 Company Overview
    • 12.1.5.2 Role of BGI Group in the Global Rare Disease Genetic Testing Market
    • 12.1.5.3 Financials
    • 12.1.5.4 Recent Developments
    • 12.1.5.5 Analyst Perspective
  • 12.1.6 CENTOGENE N.V.
    • 12.1.6.1 Company Overview
    • 12.1.6.2 Role of CENTOGENE N.V. in the Global Rare Disease Genetic Testing Market
    • 12.1.6.3 Financials
    • 12.1.6.4 Recent Developments
    • 12.1.6.5 Analyst Perspective
  • 12.1.7 Eurofins Scientific SE
    • 12.1.7.1 Company Overview
    • 12.1.7.2 Role of Eurofins Scientific SE in the Global Rare Disease Genetic Testing Market
    • 12.1.7.3 Financials
    • 12.1.7.4 Recent Developments
    • 12.1.7.5 Analyst Perspective
  • 12.1.8 GeneDx, Holdings Corp.
    • 12.1.8.1 Company Overview
    • 12.1.8.2 Role of GeneDx, Holdings Corp. in the Global Rare Disease Genetic Testing Market
    • 12.1.8.3 Financials
    • 12.1.8.4 Recent Developments
    • 12.1.8.5 Analyst Perspective
  • 12.1.9 Azenta U.S., Inc. (GENEWIZ, Inc.)
    • 12.1.9.1 Company Overview
    • 12.1.9.2 Role of Azenta U.S., Inc. (GENEWIZ, Inc.) in the Global Rare Disease Genetic Testing Market
    • 12.1.9.3 Financials
    • 12.1.9.4 Recent Developments
    • 12.1.9.5 Analyst Perspective
  • 12.1.10 Illumina, Inc.
    • 12.1.10.1 Company Overview
    • 12.1.10.2 Role of Illumina, Inc. in the Global Rare Disease Genetic Testing Market
    • 12.1.10.3 Financials
    • 12.1.10.4 Recent Developments
    • 12.1.10.5 Analyst Perspective
  • 12.1.11 Invitae Corporation
    • 12.1.11.1 Company Overview
    • 12.1.11.2 Role of Invitae Corporation in the Global Rare Disease Genetic Testing Market
    • 12.1.11.3 Financials
    • 12.1.11.4 Recent Developments
    • 12.1.11.5 Analyst Perspective
  • 12.1.12 Laboratory Corporation of America Holdings
    • 12.1.12.1 Company Overview
    • 12.1.12.2 Role of Laboratory Corporation of America Holdings in the Global Rare Disease Genetic Testing Market
    • 12.1.12.3 Financials
    • 12.1.12.4 Recent Developments
    • 12.1.12.5 Analyst Perspective
  • 12.1.13 Medgenome
    • 12.1.13.1 Company Overview
    • 12.1.13.2 Role of Medgenome in the Global Rare Disease Genetic Testing Market
    • 12.1.13.3 Recent Developments
    • 12.1.13.4 Analyst Perspective
  • 12.1.14 Myriad Genetics, Inc.
    • 12.1.14.1 Company Overview
    • 12.1.14.2 Role of Myriad Genetics, Inc. in the Global Rare Disease Genetic Testing Market
    • 12.1.14.3 Financials
    • 12.1.14.4 Recent Developments
    • 12.1.14.5 Analyst Perspective
  • 12.1.15 OPKO Health, Inc.
    • 12.1.15.1 Company Overview
    • 12.1.15.2 Role of OPKO Health, Inc. in the Global Rare Disease Genetic Testing Market
    • 12.1.15.3 Financials
    • 12.1.15.4 Recent Developments
    • 12.1.15.5 Analyst Perspective
  • 12.1.16 PerkinElmer, Inc.
    • 12.1.16.1 Company Overview
    • 12.1.16.2 Role of PerkinElmer, Inc. in the Global Rare Disease Genetic Testing Market
    • 12.1.16.3 Financials
    • 12.1.16.4 Key Insights about the Financial Health of the Company
    • 12.1.16.5 Recent Developments
    • 12.1.16.6 Analyst Perspective
  • 12.1.17 Exact Sciences Corporation (Prevention Genetics)
    • 12.1.17.1 Company Overview
    • 12.1.17.2 Role of Exact Sciences Corporation (Prevention Genetics) in the Global Rare Disease Genetic Testing Market
    • 12.1.17.3 Financials
    • 12.1.17.4 Recent Developments
    • 12.1.17.5 Analyst Perspective
  • 12.1.18 QIAGEN N.V.
    • 12.1.18.1 Company Overview
    • 12.1.18.2 Role of QIAGEN N.V. in the Global Rare Disease Genetic Testing Market
    • 12.1.18.3 Financials
    • 12.1.18.4 Recent Developments
    • 12.1.18.5 Analyst Perspective
  • 12.1.19 Quest Diagnostics Incorporated
    • 12.1.19.1 Company Overview
    • 12.1.19.2 Role of Quest Diagnostics Incorporated in the Global Rare Disease Genetic Testing Market
    • 12.1.19.3 Financials
    • 12.1.19.4 Analyst Perspective
  • 12.1.20 Strand Life Science Pvt Ltd.
    • 12.1.20.1 Company Overview
    • 12.1.20.2 Role of Strand Life Science Pvt Ltd. in the Global Rare Disease Genetic Testing Market
    • 12.1.20.3 Recent Developments
    • 12.1.20.4 Analyst Perspective

관련자료